AbbVie is launching a US and Europe based golden ticket. The award consists of one golden ticket, which provides one year of fully paid individual bench, a desk and membership at one of BioLabs’ operating locations in the US, France or Germany. The award is intended for early-stage biotech companies working on research and development in the Field of immunology, neurosciences, oncology, aesthetics, and obesity.​ Additional eligibility requirements are listed below.​
​
Terms & Conditions
Each applicant must acknowledges that they have read the official Terms and Conditions and they fully agrees and accept them.
Golden Ticket Benefits
Application requirements
AbbVie is looking for biotech companies that fit the following criteria:​
-
Have primary business location in US, France or Germany
-
Be an early stage-startup focused on developing novel therapeutic approaches for immunology,neurosciences, oncology, aesthetics, and obesity​
-
More detailed information about these research areas can be found here
-
Excluded are devices, diagnostics and similar technologies.
-
For additional requirements refer to the Terms and Conditions document.
The Application Process
01
Submit applications by
April 30, 2026
02
A subset of applications will be identified as finalist by the contest judges by
May 08, 2026
03
Finalists will present their company & scientific concept at a virtual event
on May (Date TBC)
04
One Golden Ticket will be awarded to one winner
Contact Us
If you have any questions about this Golden Ticket,
contact: global_goldenticket@abbvie.com
​
For any questions about BioLabs,
contact: goldenticket@biolabs.io
